- Home
- BLRX vs CALC Comparison
BLRX vs CALC Comparison
Compare BLRX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- CALC
- Stock Information
- Founded
- BLRX 2003
- CALC 2011
- Country
- BLRX Israel
- CALC United States
- Employees
- BLRX N/A
- CALC N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- CALC Health Care
- Exchange
- BLRX Nasdaq
- CALC Nasdaq
- Market Cap
- BLRX 36.0M
- CALC 40.3M
- IPO Year
- BLRX 2011
- CALC N/A
- Fundamental
- Price
- BLRX $0.20
- CALC $2.76
- Analyst Decision
- BLRX Strong Buy
- CALC Strong Buy
- Analyst Count
- BLRX 2
- CALC 5
- Target Price
- BLRX $5.50
- CALC $18.20
- AVG Volume (30 Days)
- BLRX 1.7M
- CALC 69.1K
- Earning Date
- BLRX 11-25-2024
- CALC 11-13-2024
- Dividend Yield
- BLRX N/A
- CALC N/A
- EPS Growth
- BLRX N/A
- CALC N/A
- EPS
- BLRX N/A
- CALC N/A
- Revenue
- BLRX $21,991,000.00
- CALC N/A
- Revenue This Year
- BLRX N/A
- CALC N/A
- Revenue Next Year
- BLRX N/A
- CALC N/A
- P/E Ratio
- BLRX N/A
- CALC N/A
- Revenue Growth
- BLRX N/A
- CALC N/A
- 52 Week Low
- BLRX $0.19
- CALC $2.05
- 52 Week High
- BLRX $1.68
- CALC $8.38
- Technical
- Relative Strength Index (RSI)
- BLRX 25.94
- CALC 34.02
- Support Level
- BLRX $0.23
- CALC $2.67
- Resistance Level
- BLRX $0.56
- CALC $2.90
- Average True Range (ATR)
- BLRX 0.03
- CALC 0.26
- MACD
- BLRX 0.00
- CALC 0.00
- Stochastic Oscillator
- BLRX 11.82
- CALC 50.35
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.